Cancer immunotherapy startup Curon Biopharmaceutical has raised $150m in series A funding from backers including Temasek and 6 Dimensions Capital.

China-based immuno-oncology therapy developer Curon Biopharmaceutical has closed a $150m series A round that included 6 Dimensions Capital, the venture capital firm co-founded by pharmaceutical research firm WuXi AppTec.

Private equity firm Boyu Capital and Singaporean government-owned investment firm Temasek also contributed to the round.

Curon is working on immunotherapy drugs that will target cancer. It will use the series A funds to support development of its pipeline, with a view to moving product candidates into preclinical and clinical testing while also expanding that pipeline.

The funding was disclosed alongside the appointment of Paul H. Song, who was most recently vice-president of electronics producer Samsung’s biosimilar development subsidiary, Samsung Bioepis, as Curon’s chief scientific officer.

Leon Chen, 6 Dimensions Capital’s founding partner and CEO, said: “Curon Biopharma represents another key strategic move by 6 Dimensions Capital in the immuno-oncology space.

“The company’s portfolio pipeline consists of multiple class-leading cancer immunotherapeutic agents in the world that could address the shortcomings of current cancer treatment paradigm.”